Verve Therapeutics
Payal is an associate scientist, editor development at Verve. Prior to joining Verve, Payal was a senior research associate in the research and development group at Modalis Therapeutics, where she worked on developing therapeutics to treat rare genetic diseases using CRISPR-Cas9 technology. She has diverse expertise in molecular biology, cell culture, screening, and assay development. Payal received her Master of Science in biotechnology from New York University and Bachelor of Engineering in biotechnology from the University of Mumbai.
Verve Therapeutics
59 followers
Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.